We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+10.28%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$153M
AUM Growth
+$6.81M
Cap. Flow
+$11.7M
Cap. Flow %
7.6%
Top 10 Hldgs %
82.43%
Holding
41
New
10
Increased
2
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
APLT
Applied Therapeutics
APLT
+$3.75M
2
ELTX icon
Elicio Therapeutics
ELTX
+$1.16M
3
BAH icon
Booz Allen Hamilton
BAH
+$1.09M
4
CVS icon
CVS Health
CVS
+$1.06M
5
ANET icon
Arista Networks
ANET
+$1.03M

Top Sells

Rank Stock Value
1
AVXL icon
Anavex Life Sciences
AVXL
+$3.62M
2
MTEM
Molecular Templates, Inc.
MTEM
+$1.07M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$52.6K

Sector Composition

Rank Sector Weight
1 Healthcare 79.18%
2 Materials 5.78%
3 Financials 2.61%
4 Technology 2.11%
5 Communication Services 1.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$58.6M 38.16%
856,844
-650
-0.1% -$52.6K
APLT
2
DELISTED
Applied Therapeutics
APLT
$19.2M 12.53%
1,025,464
+173,913
+20% +$3.75M
CRBP icon
3
Corbus Pharmaceuticals
CRBP
$170M
$9.94M 6.48%
168,196
– –
ENTX icon
4
Entera Bio
ENTX
$101M
$6.83M 4.45%
1,791,363
+50,000
+3% +$115K
ALDX icon
5
Aldeyra Therapeutics
ALDX
$91.7M
$6.76M 4.41%
569,405
– –
EIGR
6
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.14M 4%
23,141
– –
ABEO icon
7
Abeona Therapeutics
ABEO
$345M
$5.38M 3.5%
114,391
– –
BX icon
8
Blackstone
BX
$104B
$2.98M 1.94%
40,000
– –
LUMN icon
9
Lumen
LUMN
$6.53B
$2.94M 1.91%
220,000
– –
XCUR icon
10
Exicure
XCUR
$11.2M
$2.79M 1.82%
8,519
– –
DOW icon
11
Dow Inc
DOW
$21.6B
$1.92M 1.25%
30,000
– –
CTVA icon
12
Corteva
CTVA
$59.7B
$1.4M 0.91%
30,000
– –
SNGX icon
13
Soligenix
SNGX
$5.5M
$1.21M 0.79%
3,286
– –
MO icon
14
Altria Group
MO
$122B
$1.16M 0.76%
+22,700
New +$1.02M
DD icon
15
DuPont de Nemours
DD
$18.6B
$1.16M 0.76%
11,950
– –
GLW icon
16
Corning
GLW
$126B
$1.16M 0.75%
+26,600
New +$1.02M
CVS icon
17
CVS Health
CVS
$137B
$1.09M 0.71%
+14,500
New +$1.06M
ELTX icon
18
Elicio Therapeutics
ELTX
$78.8M
$1.08M 0.71%
+6,000
New +$1.16M
BAH icon
19
Booz Allen Hamilton
BAH
$8.7B
$1.05M 0.68%
+13,000
New +$1.09M
VMW
20
DELISTED
VMware, Inc
VMW
$1.05M 0.68%
+6,950
New +$993K
ANET icon
21
Arista Networks
ANET
$219B
$1.04M 0.68%
+55,200
New +$1.03M
V icon
22
Visa
V
$677B
$1.03M 0.67%
+4,850
New +$1.02M
TMO icon
23
Thermo Fisher Scientific
TMO
$211B
$958K 0.62%
+2,100
New +$1M
BTAI icon
24
BioXcel Therapeutics
BTAI
$26.2M
$863K 0.56%
1,250
– –
ALT icon
25
Altimmune
ALT
$539M
$707K 0.46%
50,000
– –
1
2

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Knoll Capital Management held 41 positions worth $153M, up 4.6% from $147M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Knoll Capital Management deployed $11.7M of net new capital in Q1 2021, opening 10 new positions and adding to 2 existing holdings. Its largest new stake was Elicio Therapeutics: 6,000 shares worth $1.08M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 86% a quarter earlier, followed by Materials and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $52.6K trimmed.

  • Knoll Capital Management's largest Q1 2021 buy was Elicio Therapeutics: 6,000 shares worth $1.08M.
  • Knoll Capital Management added most to Applied Therapeutics in Q1 2021, an estimated $3.75M increase.
  • Knoll Capital Management's biggest Q1 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $52.6K.
  • Knoll Capital Management fully exited Anavex Life Sciences in Q1 2021, selling an estimated $3.62M.
  • Knoll Capital Management's ten largest holdings make up 82% of its $153M portfolio in Q1 2021.
  • Knoll Capital Management opened 10 new positions and closed 2 in Q1 2021.
  • Knoll Capital Management's portfolio value rose 4.6% quarter-over-quarter to $153M.

Based on Knoll Capital Management's 13F filing for Q1 2021, filed 14 Jun 2021.